|
|
Blood, 15 November 2007, Vol. 110, No. 10, pp. 3499-3506.
Prepublished online as a Blood First Edition Paper on July 30, 2007; DOI 10.1182/blood-2007-02-069716.
 Previous Article | Table of Contents | Next Article 
REVIEW IN TRANSLATIONAL HEMATOLOGY
Immunomodulatory properties of mesenchymal stromal cells
Alma J. Nauta1, and
Willem E. Fibbe1
1 Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands
Mesenchymal stem cells (MSCs) are multipotential nonhematopoietic progenitor cells capable of differentiating into multiple lineages of the mesenchyme. MSCs have emerged as a promising therapeutic modality for tissue regeneration and repair. Further clinical interest has been raised by the observation that MSCs are immunoprivileged and, more importantly, display immunomodulatory capacities. Although the mechanisms underlying the immunosuppressive effects of MSCs have not been clearly defined, their immunosuppressive properties have already been exploited in the clinical setting. The aim of this review is to critically discuss the immunogenicity and immunomodulatory properties of MSCs, both in vitro and in vivo, the possible underlying mechanisms, the potential clinical use of MSCs as modulators of immune responses in vivo, and to indicate clinical safety concerns and recommendations for future research.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
O. Jones, A Lacson, X Zeng, J. Jones, K Katti, R. Cahill, and A. Ahmed
Long-term follow-up after non-myeloablative transplant of bone and marrow in BXSB mice
Lupus,
August 1, 2009;
18(9):
813 - 821.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. A. Matthay
Mesenchymally "stemming" angiogenesis
Blood,
April 30, 2009;
113(18):
4131 - 4132.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Maby-El Hajjami, P. Ame-Thomas, C. Pangault, O. Tribut, J. DeVos, R. Jean, N. Bescher, C. Monvoisin, J. Dulong, T. Lamy, et al.
Functional Alteration of the Lymphoma Stromal Cell Niche by the Cytokine Context: Role of Indoleamine-2,3 Dioxygenase
Cancer Res.,
April 1, 2009;
69(7):
3228 - 3237.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Huang, P. Johnston, B. Zhang, A. Zakari, T. Chowdhry, R. R. Smith, E. Marban, H. Rabb, and K. L. Womer
Kidney-Derived Stromal Cells Modulate Dendritic and T Cell Responses
J. Am. Soc. Nephrol.,
April 1, 2009;
20(4):
831 - 841.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Compte, A. M. Cuesta, D. Sanchez-Martin, V. Alonso-Camino, J. L. Vicario, L. Sanz, and L. Alvarez-Vallina
Tumor Immunotherapy Using Gene-Modified Human Mesenchymal Stem Cells Loaded into Synthetic Extracellular Matrix Scaffolds
Stem Cells,
March 1, 2009;
27(3):
753 - 760.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Prigione, F. Benvenuto, P. Bocca, L. Battistini, A. Uccelli, and V. Pistoia
Reciprocal Interactions Between Human Mesenchymal Stem Cells and {gamma}{delta} T Cells Or Invariant Natural Killer T Cells
Stem Cells,
March 1, 2009;
27(3):
693 - 702.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. Vela, G. V. Silva, J. A.R. Assad, A. L.S. Sousa, S. Coulter, M. R. Fernandes, E. C. Perin, J. T. Willerson, and L. M. Buja
Histopathological Study of Healing After Allogenic Mesenchymal Stem Cell Delivery in Myocardial Infarction in Dogs
J. Histochem. Cytochem.,
February 1, 2009;
57(2):
167 - 176.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Rafei, J. Hsieh, S. Fortier, M. Li, S. Yuan, E. Birman, K. Forner, M.-N. Boivin, K. Doody, M. Tremblay, et al.
Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction
Blood,
December 15, 2008;
112(13):
4991 - 4998.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Burchfield, M. Iwasaki, M. Koyanagi, C. Urbich, N. Rosenthal, A. M. Zeiher, and S. Dimmeler
Interleukin-10 From Transplanted Bone Marrow Mononuclear Cells Contributes to Cardiac Protection After Myocardial Infarction
Circ. Res.,
July 18, 2008;
103(2):
203 - 211.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Weiss, J. K. Kolls, L. A. Ortiz, A. Panoskaltsis-Mortari, and D. J. Prockop
Stem Cells and Cell Therapies in Lung Biology and Lung Diseases
Proceedings of the ATS,
July 15, 2008;
5(5):
637 - 667.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Atoui, D. Shum-Tim, and R. C.J. Chiu
Myocardial Regenerative Therapy: Immunologic Basis for the Potential "Universal Donor Cells"
Ann. Thorac. Surg.,
July 1, 2008;
86(1):
327 - 334.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Abdi, P. Fiorina, C. N. Adra, M. Atkinson, and M. H. Sayegh
Immunomodulation by Mesenchymal Stem Cells: A Potential Therapeutic Strategy for Type 1 Diabetes
Diabetes,
July 1, 2008;
57(7):
1759 - 1767.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. C. Lund, J. Tolar, and P. J. Orchard
Granulocyte colony-stimulating factor mobilized CFU-F can be found in the peripheral blood but have limited expansion potential
Haematologica,
June 1, 2008;
93(6):
908 - 912.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Morandi, L. Raffaghello, G. Bianchi, F. Meloni, A. Salis, E. Millo, S. Ferrone, V. Barnaba, and V. Pistoia
Immunogenicity of Human Mesenchymal Stem Cells in HLA-Class I-Restricted T-Cell Responses Against Viral or Tumor-Associated Antigens
Stem Cells,
May 1, 2008;
26(5):
1275 - 1287.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. C.J. Chiu
The Challenge of "Tending the Bridge"
Ann. Thorac. Surg.,
April 1, 2008;
85(4):
1149 - 1150.
[Full Text]
[PDF]
|
|
|
|
|
